Fate Therapeutics (FATE) reported second-quarter 2026 revenue of $2.1 million and a net loss of $30.2 million, or $0.25 per share. Cash, cash equivalents and investments totaled $153.8 million at June 30, 2026.
The company reported dosing the first patient in its RECLAIM-LN Phase 2 trial of FT819 for lupus nephritis and said the FDA cleared the IND application for FT839, its dual CD19/CD38-targeting CAR T-cell product candidate.
- Second-quarter revenue was $2.1 million, compared with $1.9 million a year earlier.
- Total operating expenses were $33.2 million, including $24.4 million in research and development expense.
- Cash, cash equivalents and investments declined by $21 million during the quarter; the company expects its operating runway to extend into 2028.
- RECLAIM-LN is expected to enroll about 53 patients, with enrollment targeted for completion in the first half of 2028.
- Fate appointed Laura Hamill to its board of directors.
$FATE Insider Trading Activity
$FATE insiders have traded $FATE stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $FATE stock by insiders over the last 6 months:
- BAHRAM VALAMEHR (President and CEO) sold 43,947 shares for an estimated $108,100
- CINDY TAHL (See Remarks) sold 38,800 shares for an estimated $95,405
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$FATE Hedge Fund Activity
We have seen 75 institutional investors add shares of $FATE stock to their portfolio, and 60 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 2,769,719 shares (-27.5%) from their portfolio in Q2 2026, for an estimated $7,478,241
- AQR CAPITAL MANAGEMENT LLC added 1,839,516 shares (+158.3%) to their portfolio in Q1 2026, for an estimated $2,207,419
- TWO SIGMA INVESTMENTS, LP added 1,732,722 shares (+99.9%) to their portfolio in Q1 2026, for an estimated $2,079,266
- VESTAL POINT CAPITAL, LP removed 1,725,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,070,000
- STATE STREET CORP removed 1,704,245 shares (-75.3%) from their portfolio in Q2 2026, for an estimated $4,601,461
- POINT72 ASSET MANAGEMENT, L.P. removed 1,484,867 shares (-97.2%) from their portfolio in Q1 2026, for an estimated $1,781,840
- UBS GROUP AG added 1,418,191 shares (+351.5%) to their portfolio in Q1 2026, for an estimated $1,701,829
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
